REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 15, 2021 at 03:14 am EST
Share
REYON Pharmaceutical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 0.00012 million compared to KRW 0.00007 million a year ago. Net income was KRW 14.46 million compared to KRW 882.43 million a year ago. Basic earnings per share from continuing operations was KRW 1 compared to KRW 50 a year ago. Diluted earnings per share from continuing operations was KRW 1 compared to KRW 50 a year ago. Basic earnings per share was KRW 1 compared to KRW 50 a year ago.
For the nine months, sales was KRW 0.00044 million compared to KRW 0.0003 million a year ago. Net income was KRW 4,071.62 million compared to KRW 2,266.18 million a year ago. Basic earnings per share from continuing operations was KRW 230 compared to KRW 128 a year ago. Diluted earnings per share from continuing operations was KRW 228 compared to KRW 128 a year ago. Basic earnings per share was KRW 230 compared to KRW 128 a year ago. Diluted earnings per share was KRW 228.
REYON PHARMACEUTICAL Co. Ltd. is a Korea-based company engaged in the provision of pharmaceutical products. The Companyâs products consist of remedies for circulatory systems, endocrine systems, digestive systems, respiratory systems, urinary systems and nervous systems, as well as eye drops, antibiotics, fever reducers, painkillers, anti-inflammatory drugs, antihistaminic agents, enzyme preparations, arthritis remedies, antitumor drugs and topical anesthetics, among others. It also produces pharmaceutical raw materials, such as arbekacin sulfate, alibendol, carvedilol, enocitabine, gemcitabine, glimepiride, lamotrigine, meloxicam, oxaliplatin, pioglitazone hydrochloride, ramipril, streptokinase, tacrolimus, thioctic acid, teicoplanin, voglibose and others.
REYON PHARMACEUTICAL CO., LTD. 
